N/A N=15 CoolSculpting Treatment in the Upper Arms
Body Fat Disorder
Primary: Proportion of Correctly Identified Pre-treatment Photos — 26 photos
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=85 Does More Practice Improve Arm Movement After Stroke?
Stroke
Primary: Change in Action Research Arm Test (ARAT) Score Per Week — 0.4; -0.05; 0.31; 0.66 change in units on a scale/week — p=.01
N/A N=37 Forearm Immobilization, Metabolic Health, and Muscle Loss
Healthy
Primary: Percent Change in Forearm Glucose Uptake — -73; 127; -95 Percent change in clamp FGU with immob
N/A N=361 Arm Rehabilitation Study After Stroke
Stroke · Brain Infarction · Brain Ischemia
Primary: Wolf Motor Function Test (WMFT) Log-transformed Time — -0.8; -0.9; -0.8 log(seconds)
N/A N=12 Effect of Pneumatic Tourniquet on Arm Swelling After Lymph Node Removal
Healthy Subject
Primary: Change in Hand Volume Following Tourniquet Use — 15.0; 12.1; 12.5; 7.9 mL
N/A N=13 Rehabilitation of the Upper Extremity With Enhanced Proprioceptive Feedback Following Incomplete Spinal Cord Injury
Spinal Cord Injury · Tetraplegia · Paresis
Primary: Grasp Release Test — 58.5; 72.0; 77.5 Objects moved — p=<0.025
N/A N=13 Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
Phase 2 N=18 Early Insulin and Development of ARDS
Respiratory Distress Syndrome, Adult · Sepsis · Hyperglycemia
Primary: Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen
Phase 3 N=24 Arimoclomol in Sporadic Inclusion Body Myositis
Inclusion Body Myositis
Primary: Count of Adverse Events Reported — 109; 52 adverse events reported
N/A N=31 Handgrip Exercise for Arteriovenous Fistula Maturation
Chronic Kidney Disease
Primary: Venous Diameter. — 5.78; 6.42 mm
N/A N=34 Robotic Brace Incorporating Electromyography for Moderate Affected Arm Impairment After Stroke
Hemiparesis
Primary: Impairment in the Affected Upper Extremity as Measured by the Fugl Meyer Scale. — 19.6; 18.0; 17.6 units on a scale
N/A N=35 Comparing Different Rehabilitation Exercise Strategies for Improving Arm Recovery After Stroke
Stroke
Primary: Fugl-Meyer Arm Motor Assessment Score (FMAMA) — 11.8; 6.9; 18.6; 19.2 score on a scale
N/A N=10 Robot-Assisted Therapy and Motor Learning: An Active Learning Program for Stroke
Stroke
Primary: Change From Baseline in Fugl-Meyer Assessment (FMA) - Upper Extremity Subtest — 11.0; 2.0; 8.5 score on a scale
N/A N=37 Evaluation of the Ulthera® System for Treatment of the Brachia
Brachial Ptosis
Primary: Improvement in Obtaining Lift and Tightening of Brachial Skin Laxity — 48 percentage of participants improved
Phase 2 N=4 ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
Viral Infection
Primary: Number of Participants With a DLT — 0; 0; 0; 3 Participants
N/A N=115 Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer
Breast Cancer · Arthralgia · Obesity
Primary: Effect of Change in Body Mass Index on Change in Grip Strength With Aromatase Inhibitor Therapy — -0.15; 2.44 kg/m^2 — p=0.03
N/A N=72 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
Lymphatic Filariasis
Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale
N/A N=62 Evaluation of Robotic Arm Rehabilitation in Stroke Patients
Stroke
Primary: Upper Extremity Portion of the Fugl-Meyer Motor Performance Assessment — 3.27; 2.51; 1.82 units on a scale — p=.025
Phase 2 N=15 Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients
Diabetes · Infection
Primary: Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With…
N/A N=42 Addressing Arm Non-use by Encouraging Idle-time Activity During Early Recovery From Stroke
Stroke · Exercise
Primary: Ratio of Average Activity Duration (RAAD) — 1.223 ratio
N/A N=18 Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
Multiple Sclerosis · Pathologic Processes · Demyelinating Diseases
Primary: Stabilization of Scores Using the Test d'Evaluation de la Performance Des Membres Supérieurs Des Personnes Agées (TEMPA) -Translasted in English to Mean "Performance…
Phase 2 N=26 Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
Melanoma
Primary: Progression Free Survival at One Year. — 58 percentage of participants PFS at 1 year
N/A N=168 The Effect of Questionnaire Content on Measures of Pain Intensity, Magnitude of Disability, and Symptoms of Depression in Patients With Arm Illness
Arm Illness
Primary: Patient Reported Outcomes Measurement Information System (PROMIS) Upper Extremity — 39; 43; 41 T-score
N/A N=62 Factors Associated With Radiographic Pathophysiology for Trapeziometacarpal Arthrosis in Patients Not Seeking Care for This Condition
Trapeziometacarpal Arthrosis
Primary: Factors Associated With Eaton Classification of Trapeziometacarpal Arthrosis: Age — 61; 66; 75 Years
N/A N=103 Patient Targeted Upper Extremity Rehabilitation After Stroke
Stroke
Primary: Fugl-Meyer Assessment of the Upper Extremity — 4.08; 2.45 score on a scale — p=0.912
N/A N=15 Fatiguing Arm Exercise Following Stroke
Stroke
Primary: Short Intracortical Inhibition (SICI) — 0.83; 1.14; 0.89; 0.88 SICI ratio — p=0.15
N/A N=7 Upper Extremity Rehabilitation With the BURT Robotic Arm
Stroke · Hemiparesis
Primary: Changes From Baseline in Fugl-Meyer Upper Extremity Scores — 3.50 score on a scale
N/A N=58 Predicting Ipsilesional Motor Deficits in Stroke With Dynamic Dominance Model
Stroke
Primary: Change in Jebsen-Taylor Hand Function Test (JTHFT) Times From Baseline 2 to Post Test 1 — 5.07; -.11 seconds — p=<.05
N/A N=16 Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm
Subclavian Steal
Primary: Change of Subclavian Flow to Normal Flow Pattern During Cuff Test — 0; 2 participants
N/A N=4 Active Powered Prosthesis (APEX) for Spinal Cord Injury
Spinal Cord Injuries
Primary: User Ability to Operate the APEX Device — 4; 4 Participants